ReviewJournal of the Chinese Medical Association : JCMA2022
To do one and to get more: Part II. Diabetes and metabolic dysfunction-associated fatty liver diseases.
Review in Journal of the Chinese Medical Association : JCMA, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Considerations in Imaging-Based Assessment of Steatotic Liver Disease to Enhance Harmonization, Longitudinal Interpretation, and Clinical Implementation.Korean journal of radiology · 2026Article
- Are prioritizing and allocating expensive adjuvant and maintenance therapies beneficial in cancer care?Journal of the Chinese Medical Association : JCMA · 2026Article
- S100A8/A9-activated IFNγCellular and molecular life sciences : CMLS · 2024Article
- MiR-337-3p improves metabolic-associated fatty liver disease through regulation of glycolipid metabolism.iScience · 2023Article
- Winners of the 2022 honor awards for excellence at the annual meeting of the Chinese Medical Association-Taipei: Part II.Journal of the Chinese Medical Association : JCMA · 2023Article
- Diabetes mellitus in pregnancy increases the risk of birth defects of newborns.Journal of the Chinese Medical Association : JCMA · 2023Article
- Is the relation between three comorbidities and carotid atherosclerosis dependent on the sum or not?Journal of the Chinese Medical Association : JCMA · 2023Article
- Minimally invasive surgery for hepatocellular carcinoma.Journal of the Chinese Medical Association : JCMA · 2023Article
- The impact of hyperlipidemia and carotid atherosclerosis.Journal of the Chinese Medical Association : JCMA · 2023Article
- Is the weight of hypertension heavier than dyslipidemia and diabetes mellitus on carotid atherosclerosis?Journal of the Chinese Medical Association : JCMA · 2023Article
- The impact of adding mitomycin-C to radiotherapy plus oral tegafur-uracil on advanced-stage rectal cancer.Journal of the Chinese Medical Association : JCMA · 2023Article
- A trend to minimize the radicality of surgery.Journal of the Chinese Medical Association : JCMA · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (DM) is characterized by inability of faulty pancreatic β-cells to secret a normal amount of insulin to maintain normal body consumption, and/or peripheral tissue has a decreased susceptibility to insulin, resulting in hyperglycemia and insulin resistance. Similar to other chronic systemic inflammatory diseases, DM is a result from dysregulated interactions between ethnic, genetic, epigenetic, immunoregulatory, hormonal, and environmental factors. Therefore, it is rational to suppose the concept as "To do one and to get more", while using antidiabetic agents (ADA), a main pharmacologic agent for the treatment of DM, can provide an extraglycemia effect on comorbidities or concomittent comorbidities to DM. In this review, based on the much strong correlation between DM and metabolic dysfunction-associated fatty liver diseases (MAFLD) shown by similar pathophysiological mechanisms and a high prevalence of DM in MAFLD and its vice versa (a high prevalence of MAFLD in DM), it is possible to use the strategy to target both diseases simultaneously. We focus on a new classification of ADA, such as glucagon-like peptide-1 receptor (GLP1R) agonist and sodium-glucose cotransporter-2 (SGLT-2) inhibitors to show the potential benefits of extraglycemic effect on MAFLD. We conclude that the management of DM patients, especially for those who need ADA as adjuvant therapy should include healthy lifestyle modification to overcome the metabolic syndrome, contributing to the urgent need of an effective weight-reduction strategy. GLP1R agonist is one of effective body weight-lowering medications, which may be a better choice for DM complicated with MAFLD or its-associated severe form as metabolic associated steatohepatitis (MASH), although the role of SGLT-2 inhibitors is also impressive. The prescription of these two classes of ADA may satisfy the concept "To do one and to get more", based on successful sugar-lowering effect for controlling DM and extraglycemia benefits of hepatoprotective activity in DM patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.